

Appl. No. : 10/828,795
Filed : April 21, 2004

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1-7. (CANCELED)

8. (CURRENTLY AMENDED) ~~The composition of claim 1, A composition for affecting weight loss comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and said second compound is fluoxetine~~ bupropion, or a pharmaceutically acceptable salt or prodrug thereof.

9. (CURRENTLY AMENDED) ~~The composition of claim 1~~ 8, wherein said first compound is naltrexone and said second compound is bupropion.

10. (CURRENTLY AMENDED) A method of affecting weight loss, comprising identifying an individual in need thereof and treating that individual ~~to antagonize opioid receptor activity and to enhance α -MSH activity~~ with a composition comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.

11. (ORIGINAL) The method of claim 10, wherein said individual has a body mass index greater than 25.

12-18. (CANCELED)

19. (CURRENTLY AMENDED) ~~The method of claim 1~~ 10, wherein said first compound and said second compound are administered nearly simultaneously.

20-21. (CANCELED)

22. (NEW) The method of claim 10, wherein said first compound is administered prior to said second compound.

23. (NEW) The method of claim 10, wherein said first compound is administered subsequent to said second compound.

24. (NEW) The method of claim 10, wherein said individual is not suffering from depression.

25. (NEW) The method of claim 10, wherein said first compound is naltrexone and said second compound is bupropion.

Appl. No. : **10/828,795**
Filed : **April 21, 2004**

26. (NEW) A method of increasing satiety in an individual comprising identifying an individual in need thereof and treating that individual with a composition comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.

27. (NEW) The method of claim 26, wherein said first compound is administered prior to said second compound.

28. (NEW) The method of claim 26, wherein said first compound is administered subsequent to said second compound.

29. (NEW) The method of claim 26, wherein said individual is not suffering from depression.

30. (NEW) The method of claim 26, wherein said first compound is naltrexone and said second compound is bupropion.

31. (NEW) A method of suppressing the appetite of an individual comprising identifying an individual in need thereof and treating that individual with a composition comprising a first compound and a second compound, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.

32. (NEW) The method of claim 31, wherein said first compound is administered prior to said second compound.

33. (NEW) The method of claim 31, wherein said first compound is administered subsequent to said second compound.

34. (NEW) The method of claim 31, wherein said individual is not suffering from depression.

35. (NEW) The method of claim 31, wherein said first compound is naltrexone and said second compound is bupropion.

36. (NEW) A pharmaceutical composition comprising a first compound, a second compound, and a pharmaceutically acceptable excipient, diluent, or carrier, wherein said first compound is naltrexone, or a pharmaceutically acceptable salt or prodrug thereof, and

Appl. No. : **10/828,795**
Filed : **April 21, 2004**

wherein said second compound is bupropion, or a pharmaceutically acceptable salt or prodrug thereof.

37. (NEW) The pharmaceutical composition of claim 36, wherein said first compound is naltrexone and said second compound is bupropion.